Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Israeli health minister: Room for COVID optimism as ‘R’ drops to 0.8

“There is room for optimism,” said Health Minister Nitzan Horowitz Friday morning in a Facebook post soon after his ministry updated that the country’s reproduction rate had dropped to 0.8.
The reproduction rate or “R” is the number of people a sick person infects. It has been declining for several days now, Friday morning reaching the target that decision makers had said previously would halt the spread of coronavirus.

“The low reproduction rate provides sufficient safety margins to prevent the resumption of the outbreak as a result of the opening of the education system,” a team of Hebrew University researchers that advise the government said on Friday in a report.

Source: The Jerusalem Post

https://www.jpost.com/breaking-news/covid-numbers-nearly-8000-cases-yesterday-but-r-at-08-679127

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!